Coverage of the Arrhythmia Alliance Symposia – Arrhythmia Mapping presented at HRC 2019 and chaired by Drs Stuart Harris and Vias Markides.
Filmed at the Heart Rhythm Congress (HRC) 2019 in Birmingham, UK, October 2019 in partnership with Arrhythmia Alliance.
Trending Topic
New late-breaking data presented on Day 3 of EuroPCR 2026 highlighted evolving approaches to antiplatelet therapy, transcatheter treatment of pure aortic regurgitation and procedural optimization in bicuspid TAVR
In this interview, Dr Valentina Kutyifa, University of Rochester Medical Center, Rochester, NY, USA, offers insight into the BIO LIBRA study (ClinicalTrials.gov identifier: NCT03884608), a landmark trial designed to reassess outcomes in patients with non-ischaemic cardiomyopathy in the era of contemporary medical therapy. Recognizing that much of the original evidence supporting implantable cardioverter-defibrillator (ICD) use in this population dates back decades, the BIO LIBRA study was initiated to fill key knowledge gaps using modern treatment protocols.
In this interview, Dr Louise Olde Nordkamp, a device cardiologist at Amsterdam University Medical Center, discusses the long-term findings of the PRAETORIAN XL trial—a follow-up study comparing transvenous and subcutaneous implantable cardioverter-defibrillators (ICDs). Building on the original PRAETORIAN trial, this extended 8-year analysis evaluated device-related complications and confirmed that subcutaneous ICDs carry fewer major and lead-related complications. Dr Olde Nordkamp highlights the clinical relevance of these results, supporting broader consideration of subcutaneous ICDs in patients without pacing indications.
In this interview, Dr. Margarida Pujol-Lopez from the Hospital Clinic in Barcelona discusses the differences between conduction system pacing (CSP) and biventricular pacing (BVP) in treating heart failure. CSP is more physiological and may offer better outcomes than BVP, which fails in about 30% of patients. The CONSYST-CRT trial, comparing CSP and BVP, showed that CSP is non-inferior to BVP based on primary and secondary endpoints, including mortality, heart failure, and QRS shortening.
Revascularization for patients with ischaemic left ventricular (LV) systolic dysfunction takes one of two forms - percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG), both of which have positives and negatives. STICH, published in 2011, analysed the role of CABG in patients with LV systolic dysfunction and looked at improvement of clinical outcomes in 1,212 patients from 22 countries across the world, optimised to either optimal medical therapy or optimal medical therapy plus CABG. REVIVED-BCIS2 in 2022 looked at 700 patients in the UK with a similar patient population of 35% ejection fraction or less, randomized to PCI or optimal medical therapy. This interview dives into their analysis of the results from these exciting trials and investigation into the discrepancies between the outcomes.
The OptiVALL study aimed to assess the atrioventricular synchronous pacing capabilities of the Micra AV device, and to describe what programming changes are needed. In this touchCARDIO interview, we speak with Dr Sem Briongos Figuero (Hospital Infanta Leonor, Madrid, Spain) ...
The MARVEL 2 trial studied atrioventricular synchronous pacing in patients with a Micra leadless ventricular pacemaker. In this touchCARDIO interview, we speak with Dr Sem Briongos Figuero (Hospital Infanta Leonor, Madrid, Spain) to discuss the trials studying atrioventricular synchrony and their ...
Transcatheter edge-to-edge repair (TEER) is a minimally invasive procedure that can effectively treat functional mitral regurgitation in heart failure patients. Compared to traditional surgical approaches, TEER offers benefits such as reduced hospital stay, lower risk of bleeding and infection, and ...
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview ...
Dr Andrew Krahn, President, Heart Rhythm Society (HRS), discusses the upcoming Heart Rhythm 2023 meeting (May 19-21, 2023, New Orleans, LA, USA), and the HRX 2023 conference (September 21-23, 2023, in Seattle, WA, USA) hosted by the Heart Rhythm Society (HRS), a non-profit organization ...
The guidelines for the use of short-term dual antiplatelet therapy (DAPT) after coronary intervention vary depending on the patient's clinical situation and the type of intervention performed. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal ...
The goal of dual antiplatelet therapy (DAPT) is to reduce the risk of stent thrombosis, a potentially life-threatening complication that can occur when blood clots form in the stent. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department ...
The PROTECTED-TAVR trial studied the efficacy of using an embolic protection device (Sentinel® cerebral protection system) during transcatheter aortic valve replacement in reducing the incidence of stroke/disabling stroke. In this touchCARDIO interview, we speak with Dr Steven Messe (University ...
Keep track of your clinical interests and newsletter subscriptions.
Or use a .
Already registered? Login below.
